Search
Selected Filters
Displaying 4 news results
-
Sustained Suppression of VEGF: Looking Forward and Looking Back
The results of the LADDER trial demonstrate a major step forward but introduce many questions.
-
Gene Therapy Trials for Wet Age-Related Macular Degeneration
After a series of failed trials, current research suggests that the next generation of gene therapies for wet age-related macular degeneration holds promise. Learn how investigators are inducing the body’s cells to administer their own therapeutic response to disease activity.
-
The Assistance Fund Opens New Program for Inherited Retinal Diseases
The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today launched a new program that offers financial support for individuals with inherited retinal diseases.
-
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States
First adeno-associated viral (AAV) vector investigational candidate to reach this stage of FDA review
Investigational LUXTURNA clinical program includes up to four years of efficacy data, with observation ongoing
